Skip to main content

Table 1 Patient baseline and HIPEC characteristics

From: CT-determined sarcopenia is associated with neutropenia in patients undergoing hyperthermic intraperitoneal chemotherapy for gastrointestinal cancer

Characteristic

Total

(nā€‰=ā€‰103)

Sarcopenia

(nā€‰=ā€‰37, 35.9%)

No sarcopenia

(nā€‰=ā€‰66, 64.1%)

p

Gender

ā€ƒMale

63

23

40

0.88

ā€ƒFemale

40

14

26

Ā 

ā€‰Age (years)

56Ā (47, 63)

57Ā (52, 63.50)

56Ā (45, 63.25)

0.40

ā€‰BMI (kg/m2)

22.0Ā (19.5, 23.7)

22.5Ā (19.3, 24.0)

21.5Ā (19.5, 23.7)

0.57

ā€‰Comorbidity

43

14

29

0.55

Tumor initial location

ā€ƒStomach

67

23

44

0.65

ā€ƒColorectum

36

14

22

Ā 

ā€‰Preoperative chemotherapy

19

7

12

0.93

Preoperative test results

Ā Ā Ā Ā 

ā€ƒAlbumin (g/l)

38.20Ā (36.03, 40.98)

39.2Ā (35.85, 41.3)

38.2Ā (35.70, 41.3)

0.53

ā€ƒWBC (Ɨā€‰109/l)

5.3Ā (4.45, 6.53)

5.73Ā (4.59, 6.77)

5.14Ā (4.40, 6.37)

0.45

ā€ƒNeutrophil (Ɨā€‰109/l)

3.21Ā (2.52, 4.07)

3.49Ā (2.83, 4.06)

2.95Ā (2.46, 4.13)

0.28

Type of HIPEC

ā€ƒProphylactic

66

26

40

0.33

ā€ƒTherapeutic

37

11

26

Ā 

Session of HIPEC

ā€ƒOne

13

4

9

0.90

ā€ƒTwo

37

14

23

Ā 

ā€ƒThree

53

19

34

Ā 
  1. BMI body mass index, WBC white blood count, HIPEC hyperthermic intraperitoneal chemotherapy